Cervical cancer (CC) is a common gynecological malignancy, accounting for 10% of all gynecological cancers. Recently, targeted therapy for CC has shown unprecedented advantages. To improve CC patients’ prognosis, there are still urgent needs to develop more promising therapeutic targets. Aldo-keto reductase 1 family member C1 (AKR1C1) is a type of aldosterone reductase and plays a regulatory role in a variety of key metabolic pathways. Several studies indicated that AKR1C1 was highly expressed in a series of tumors, and participated in the progression of these tumors. However, the possible effects of AKR1C1 on CC progression remain unclear. Herein, we revealed AKR1C1 was highly expressed in human CC tissues and correlated with the clinical characteristics of patients with CC. AKR1C1 could regulate the proliferation and invasion of cervical cancer cells in vitro. Further experiments showed that AKR1C1 could regulate TWIST1 expression and AKT pathway. In summary, we confirmed the involvement of AKR1C1 in CC progression, and therefore AKR1C1 may have the potential to be a molecular target for CC treatment.

宫颈癌（CC）是常见的妇科恶性肿瘤，占所有妇科癌症的10％。最近，针对CC的靶向治疗已显示出空前的优势。为了改善CC患者的预后，仍然迫切需要开发更有希望的治疗靶标。醛糖酮还原酶1家族成员C1（AKR1C1）是醛固酮还原酶的一种，在多种关键的代谢途径中起调节作用。多项研究表明，AKR1C1在一系列肿瘤中高度表达，并参与了这些肿瘤的进展。但是，AKR1C1对CC进展的可能影响仍不清楚。在这里，我们揭示了AKR1C1在人类CC组织中高表达，并与CC患者的临床特征相关。体外。进一步的实验表明，AKR1C1可以调控TWIST1的表达和AKT途径。总之，我们证实了AKR1C1参与CC进展，因此AKR1C1可能成为CC治疗的分子靶标。